These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 38255991)

  • 1. A Water-Soluble Chitosan Derivative for the Release of Bioactive Deferoxamine.
    Michailidou G; Li Y; Zamboulis A; Karlioti G; Meimaroglou D; Pantopoulos K; Bikiaris DN
    Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38255991
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Formulation and In-Vitro Characterization of Chitosan-Nanoparticles Loaded with the Iron Chelator Deferoxamine Mesylate (DFO).
    Lazaridou M; Christodoulou E; Nerantzaki M; Kostoglou M; Lambropoulou DA; Katsarou A; Pantopoulos K; Bikiaris DN
    Pharmaceutics; 2020 Mar; 12(3):. PubMed ID: 32156022
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Injectable deferoxamine nanoparticles loaded chitosan-hyaluronic acid coacervate hydrogel for therapeutic angiogenesis.
    S V; A S; Annapoorna M; R J; Subramania I; Shantikumar V N; R J
    Colloids Surf B Biointerfaces; 2018 Jan; 161():129-138. PubMed ID: 29055865
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nanogel-DFO conjugates as a model to investigate pharmacokinetics, biodistribution, and iron chelation in vivo.
    Wang Y; Liu Z; Lin TM; Chanana S; Xiong MP
    Int J Pharm; 2018 Mar; 538(1-2):79-86. PubMed ID: 29341909
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination of deferasirox and deferoxamine in clinical practice: an alternative scheme of chelation in thalassemia major patients.
    Cassinerio E; Orofino N; Roghi A; Duca L; Poggiali E; Fraquelli M; Zanaboni L; Cappellini MD
    Blood Cells Mol Dis; 2014 Sep; 53(3):164-7. PubMed ID: 24846580
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Composite chitosan/alginate hydrogel for controlled release of deferoxamine: A system to potentially treat iron dysregulation diseases.
    Rassu G; Salis A; Porcu EP; Giunchedi P; Roldo M; Gavini E
    Carbohydr Polym; 2016 Jan; 136():1338-47. PubMed ID: 26572479
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted Co-delivery of the Iron Chelator Deferoxamine and a HIF1α Inhibitor Impairs Pancreatic Tumor Growth.
    Lang J; Zhao X; Wang X; Zhao Y; Li Y; Zhao R; Cheng K; Li Y; Han X; Zheng X; Qin H; Geranpayehvaghei M; Shi J; Anderson GJ; Hao J; Ren H; Nie G
    ACS Nano; 2019 Feb; 13(2):2176-2189. PubMed ID: 30676731
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Polymeric Nanoparticles Enhance the Ability of Deferoxamine To Deplete Hepatic and Systemic Iron.
    Guo S; Liu G; Frazer DM; Liu T; You L; Xu J; Wang Y; Anderson GJ; Nie G
    Nano Lett; 2018 Sep; 18(9):5782-5790. PubMed ID: 30085676
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Kinetics of removal and reappearance of non-transferrin-bound plasma iron with deferoxamine therapy.
    Porter JB; Abeysinghe RD; Marshall L; Hider RC; Singh S
    Blood; 1996 Jul; 88(2):705-13. PubMed ID: 8695819
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biocompatibility and toxicity of novel iron chelator Starch-Deferoxamine (S-DFO) compared to zinc oxide nanoparticles to zebrafish embryo: An oxidative stress based apoptosis, physicochemical and neurological study profile.
    Nasrallah GK; Salem R; Da'as S; Al-Jamal OLA; Scott M; Mustafa I
    Neurotoxicol Teratol; 2019; 72():29-38. PubMed ID: 30710618
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exploring the "iron shuttle" hypothesis in chelation therapy: effects of combined deferoxamine and deferiprone treatment in hypertransfused rats with labeled iron stores and in iron-loaded rat heart cells in culture.
    Link G; Konijn AM; Breuer W; Cabantchik ZI; Hershko C
    J Lab Clin Med; 2001 Aug; 138(2):130-8. PubMed ID: 11477380
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recent insights into interactions of deferoxamine with cellular and plasma iron pools: Implications for clinical use.
    Porter JB; Rafique R; Srichairatanakool S; Davis BA; Shah FT; Hair T; Evans P
    Ann N Y Acad Sci; 2005; 1054():155-68. PubMed ID: 16339661
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of the iron(III) chelator, desferrioxamine, on iron and transferrin uptake by the human malignant melanoma cell.
    Richardson D; Ponka P; Baker E
    Cancer Res; 1994 Feb; 54(3):685-9. PubMed ID: 8306330
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload.
    Piga A; Galanello R; Forni GL; Cappellini MD; Origa R; Zappu A; Donato G; Bordone E; Lavagetto A; Zanaboni L; Sechaud R; Hewson N; Ford JM; Opitz H; Alberti D
    Haematologica; 2006 Jul; 91(7):873-80. PubMed ID: 16818273
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Iron chelation cancer therapy using hydrophilic block copolymers conjugated with deferoxamine.
    Komoto K; Nomoto T; El Muttaqien S; Takemoto H; Matsui M; Miura Y; Nishiyama N
    Cancer Sci; 2021 Jan; 112(1):410-421. PubMed ID: 32770631
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enzymatically Biodegradable Polyrotaxane-Deferoxamine Conjugates for Iron Chelation.
    Liu Z; Lin TM; Purro M; Xiong MP
    ACS Appl Mater Interfaces; 2016 Oct; 8(39):25788-25797. PubMed ID: 27623539
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanisms for the shuttling of plasma non-transferrin-bound iron (NTBI) onto deferoxamine by deferiprone.
    Evans P; Kayyali R; Hider RC; Eccleston J; Porter JB
    Transl Res; 2010 Aug; 156(2):55-67. PubMed ID: 20627190
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ROS-triggered degradable iron-chelating nanogels: Safely improving iron elimination in vivo.
    Liu Z; Qiao J; Nagy T; Xiong MP
    J Control Release; 2018 Aug; 283():84-93. PubMed ID: 29792889
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Effect of sodium alginate-g-deferoxamine/chitosan microspheres on osteogenic differentiation of rat bone mesenchymal stem cells].
    Yu ML; Wu HM; Li GF; Hu MY; Chen D
    Shanghai Kou Qiang Yi Xue; 2023 Aug; 32(4):356-362. PubMed ID: 38044727
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of combined chelation treatment with pyridoxal isonicotinoyl hydrazone analogs and deferoxamine in hypertransfused rats and in iron-loaded rat heart cells.
    Link G; Ponka P; Konijn AM; Breuer W; Cabantchik ZI; Hershko C
    Blood; 2003 May; 101(10):4172-9. PubMed ID: 12511418
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.